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Abstract 
 
 
Alzheimer's disease is a neurological disorder in which the death of brain 
cells causes memory loss and cognitive decline. The role of treatment is 
not limited to pharmacology, but also involves many factors, such as the 
psychological, social, and economic aspects of the patient and family. It is 
important to consider the use of AChe inhibitors in patients with mild to 
moderate AD, despite cost issues and in the absence of any other 
immediate progression. Although there are a lots of currently available 
inhibitor for acetyl cholinesterase but there is no selective potent 
inhibitor for AD. so, there is an urgent need discover of compounds that 
are active against Acetyl cholinesterase, along with there is need of 
molecular modeling for identifying functional groups that may be 
important for inhibiting Acetyl cholinesterase activity. 
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Introduction 
 
Alzheimer’s disease (AD) is a progressive 
degenerative brain disease of unknown origin 
with atrophy of the cerebral cortex, including 
plaques and tangles of nerve granules.1 It 
develops with age, although there is no 
evidence that it is caused by the ageing 
process and is linked to genetics, lifestyle, and 
environmental factors that affect brain cells 
over time. In the initial stages of the disease, 
arise from forgetfulness and mild confusion. 
As time goes on, recent memories begin to 
fade. It manifests itself in memory loss, 
personality change and eventually dementia.2 
 
 
Pathogenesis, Clinical features, Role of 
acetylcholinesterase inhibitors and Recent 
developments 
 
Pathogenesis- Alzheimer’s disease is 
associated with a lack of acetylcholine (ACh), 
a neurotransmitter in the brain. The ACh is 
regulated by the hydrolytic enzyme acetyl 
cholinesterase (AChE), which rapidly degrades 
ACh both in the periphery and the brain.3 The 
Ach also inhibits the release of cytokines by 
the cholinergic anti-inflammatory pathway. 
The abnormal cholinergic system is associated 
with mental impairment and a series loss of 
cholinergic function in the central nervous 
system and contribute to cognitive 
symptoms.4 
 
Clinical features- The preclinical stage of AD is 
unclear, without reliable symptoms and signs 
for early diagnosis before the irreversible 
manifestation. In the mild dementia stage, 
difficulties with declarative memory are 
prominent; depressive symptoms are not 
infrequent, but the patient manages to live 
alone.5 Supervision is needed in the moderate 
dementia stage as other cognitive domains 
are affected, together with non-cognitive 
functions. In late stage with neurological 
disturbances, a complete dependence is 
typical of the illness. The life expectancy of 
patients is reduced, but the period of relative  
 
 
well-being may be prolonged with 
symptomatic treatment.6,7 
 
Role of acetylcholinesterase inhibitors -
Understanding the structure of AChE is 
essential for its high catalytic efficiency and 
the molecular basis for ACh recognition by 
other ACh binding proteins (ACh receptors), 
and the pharmacological and toxicological 
mechanisms of the drugs. The use of AChE 
inhibitors (AChEIs) is one aspect of the 
treatment regimen for AD.An integrated 
approach that combines drug therapy with 
multidisciplinary team assessments, 
community supports are important. Early use 
of AChe inhibitors helps in the overall 
assessment and diagnosis of AD, as not all 
patients are responsive to treatment. Families 
and caregivers need to be aware of the 
limitations of treatment.8A good discussion at 
the beginning of treatment can help avoid 
misunderstandings. Together with 
pharmacology treatment, the psychological, 
social, and economic aspects of the patient 
and caregiver are an important consideration. 
The use of AChe inhibitors in mild to 
moderate AD may be considered despite the 
cost issues.9 
 
Recent developments- To date, none of the 
pharmacological agents has shown a clear 
benefit to AD patients. The AChEIs can directly 
inhibit the production of cytokines by 
microglia and monocytes. Hence, it’s efficacy 
in part is because of the anti-inflammatory 
effects. The effect of AChEIs can be achieved 
by enhancing the transmission of AChE drug 
form neurons to neurons. The imbalance 
between the generation and removal of 
amyloid-β (Aβ) is an early and emerging factor 
in Alzheimer’s disease.10 
 
In AD, female morbidity is twice as high as 
male and terminal symptoms may vary from 
person to person. Medication can temporarily 
relieve some symptoms or slow the 
progression of the disease in some people. 
Despite various advancements, AD remains a 
problem world-wide and requires further 
development in therapies and treatments.11 
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Conclusion 
 
There are a lot of acetyl cholinesterase 
inhibitors in use, but lacks selective potent 
inhibitor for the management of Alzheimer’s 
disease. Further characterization of available 
compounds for selectivity and key protein-
ligand interactions is needed. 
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